Acetaminophen is the safest first-line acute migraine treatment for an 18-week pregnant woman who has already taken ondansetron
For this pregnant patient at 18 weeks gestation, start with acetaminophen 1000 mg (preferably as a suppository for better absorption), and if inadequate, add metoclopramide 10 mg IV (administered slowly over at least 3 minutes) as a second-line agent. Avoid NSAIDs at this gestational age due to potential fetal risks.
Treatment Algorithm for Pregnant Patients with Acute Migraine
Critical Context
The 2025 American College of Physicians guidelines 1 explicitly state their recommendations apply to "nonpregnant and nonlactating adults" and emphasize that clinicians must "discuss the adverse effects of pharmacologic treatments during pregnancy and lactation" 1. This means standard migraine protocols do not apply here—pregnancy-specific safety data must guide all decisions.
First-Line Treatment: Acetaminophen
- Dose: 1000 mg, preferably as suppository 2
- Safety profile: Considered safest option in pregnancy across all trimesters 2
- Rationale: While recent controversy exists regarding acetaminophen safety 3, it remains the most established safe option with decades of use
Second-Line Treatment: Metoclopramide
If acetaminophen fails after 1-2 hours:
- Dose: 10 mg IV administered slowly over at least 3 minutes 4
- Safety: Safe and effective in pregnancy 4
- Administration caveat: Slow IV bolus minimizes extrapyramidal side effects 4
- Timing: Can be used in second and third trimesters 2
- Combination: Can be used alone or with acetaminophen 4
Regarding the Ondansetron Already Given
The ondansetron (Zofran) she received is acceptable but requires counseling. The 2024 RCOG guideline on nausea and vomiting in pregnancy 4 states ondansetron is "safe and effective" as a second-line antiemetic, though there is "a very small increase in the absolute risk of orofacial clefting with ondansetron use in the first trimester" 4. At 18 weeks (second trimester), the critical period for orofacial development has passed, making this less concerning. The FDA label 5 classifies ondansetron as Pregnancy Category B, meaning animal studies show no harm but adequate human studies are lacking.
What to Avoid
Absolutely Contraindicated:
- Triptans: All triptans are contraindicated in pregnancy 2, 6
- Ergot alkaloids (DHE, ergotamine): Contraindicated 2
- NSAIDs (ibuprofen, naproxen): While acceptable in second trimester in some sources 2, should be avoided—particularly after 20 weeks due to risks of oligohydramnios and premature ductus arteriosus closure
- Opioids and butalbital: Not recommended for migraine generally 1, and particularly problematic in pregnancy 7
Newer Agents:
- Gepants (rimegepant, ubrogepant): Specifically noted for "nonpregnant outpatient adults" only 1
- Ditans (lasmiditan): Same restriction 1
Common Pitfalls
Applying non-pregnancy guidelines: The 2025 ACP guidelines explicitly exclude pregnant patients—do not extrapolate their triptan + NSAID recommendations to pregnancy 1
Undertreatment due to fear: A retrospective study 7 found 32% of pregnant women with migraine tried no medications before hospital presentation, and many received suboptimal treatment. Appropriate treatment is essential for maternal quality of life.
Overuse of opioids/butalbital: The same study 7 found 30% received opioids and 35% received butalbital despite these being less effective and potentially hazardous 7
Forgetting supportive measures: IV fluid bolus (used in only 38% of cases 7) and IV magnesium (24% 7) are underutilized safe options
Additional Safe Options to Consider
- IV magnesium sulfate: Safe in pregnancy, though prophylactic use has recent controversy 3
- IV fluids: Simple hydration can be effective
- Peripheral nerve blocks: Greater occipital nerve blocks are safe and underutilized (only 6% in one study 7)
- Prochlorperazine: Unlikely to be harmful for nausea 2
Prophylaxis Consideration
If migraines are frequent, only metoprolol, propranolol, fluoxetine, and magnesium are acceptable prophylactic options during pregnancy 2, 6.